Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Why now
Thesis: Lilly oral GLP-1 competitive edge vs Novo
Catalyst to watch: Head-to-head trial data or FDA decision
Main risk: Indirect comparisons are not randomized evidence
Why it matters
Indirect comparison suggests Lilly's oral GLP-1 may outcompete oral semaglutide, shifting obesity/diabetes share.
Details
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where Foundayo 9 mg and 17.2 mg delivered greater A1C and weight reductions...
Sources
- prnewswire · 2026-09-29 07:00 UTC